newsfilter
← Latest News
GlobeNewswire·

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

- Duchenne (SGT-003): Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant